Physician profile
Mohammad Ashraf
NPI 1881616159
$3,659.25
in general payments reported to CMS, 2019-2025
26 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $188 · 2021: $109 · 2022: $321 · 2023: $1,476 · 2024: $678 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $84.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.10 |
| Education | $84.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $707.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $338.11 | 2021-2025 | Verquvo |
| Dilon Technologies, INC. | $309.68 | 2023 | Hemoblast Bellows |
| Astrazeneca Pharmaceuticals Lp | $297.87 | 2022-2024 | Farxiga, Andexxa |
| Amgen INC. | $235.87 | 2019-2025 | Repatha |
| Lilly USA, LLC | $182.89 | 2019-2023 | Mounjaro, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $165.21 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $161.57 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $159.28 | 2022-2024 | Opsumit, Uptravi |
| Pfizer INC. | $149.26 | 2024-2025 | |
| Abiomed | $135.23 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $112.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $111.46 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals, Ltd. | $103.82 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $70.97 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.71 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $56.23 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $55.00 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $50.72 | 2019 | |
| Sanofi Pasteur INC. | $34.92 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $33.95 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $32.87 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $27.25 | 2024 | |
| Vifor Pharma, INC. | $27.21 | 2025 | Veltassa |
| Boston Scientific Corporation | $21.84 | 2022 | |
| Gilead Sciences, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.